Updated OAB guideline now says clinicians may consider combination therapy with an antimuscarinic and beta3-andrenoceptor agonist for patients refractory to monotherapy with either of those medications.
Velicept Therapeutics announced that solabegron met the primary endpoint in the phase 2b VEL-2002 study that evaluated patients with overactive bladder (OAB).
Urovant Sciences announced topline data from the phase 3 EMPOWUR trial which evaluated vibegron in adult patients with symptoms of overactive bladder.
Decreasing salt intake may benefit patients with nocturia who are heavy salt users, according to a new study published in Neurourology and Urodynamics. In a prospective study, Tomohiro Matsuo, MD, and colleagues from Nagasaki University Graduate School of Biomedical Sciences in Nagasaki, Japan, analyzed changes in lower urinary tract symptoms in 321 patients with nocturia…
Compared with men receiving androgen deprivation therapy for prostate cancer, healthy men had a 98% decreased risk of overactive bladder, study finds.
In a small trial, patients receiving 300 U and 500 U of intravesical abobotulinumtoxin A experienced reductions in nocturia episodes at 12 and 24 weeks.
In a study, percutaneous tibial nerve stimulation reduced nocturia episodes by 0.8 on average.
Study authors developed a Markov model with health states based on daily urinary incontinence episodes (UIEs) to compare the cost-effectiveness of onabotulinumtoxinA, implantable sacral nerve stimulation devices, percutaneous tibial nerve stimulation, anticholinergic medications, and mirabegron versus BSC for the management of refractory OAB.
The goal of bladder health month is to encourage individuals to engage in dialogue with their healthcare providers about their symptoms and to empower them to actively participate in their care.
Desmopressin reduced the number of nocturnal voids by 0.85 compared with placebo.